ABL Kinase Gene Mutation Analysis and Gleevec® Resistance Featured
Test Code
ABL G
Test Synonyms
ABL kinase domain gene sequencing
Associations
Chronic myelogenous leukemia (CML), Acute lymphoblastic leukemia (ALL), Allogeneic bone marrow transplantation, Minimal residual disease (MRD), Molecular remission, Gleevec® resistance
Methodology
Quantitative reverse transcriptase PCR (RT-PCR), Semi-nested PCR, Bi-directional DNA sequencing
CPT Codes
83891 x3 – Isolation or extraction of highly purified nucleic acid
83892 x1 – Enzymatic digestion
83902 x1 – Reverse transcription
83898 x3 – Amplification of patient nucleic acid, single primer pair, each primer pair
83894 x1 – Separation by gel electrophoresis
83904 x5 – Mutation identification by sequencing, single segment, each segment
83912-26 – Interpretation and report
83892 x1 – Enzymatic digestion
83902 x1 – Reverse transcription
83898 x3 – Amplification of patient nucleic acid, single primer pair, each primer pair
83894 x1 – Separation by gel electrophoresis
83904 x5 – Mutation identification by sequencing, single segment, each segment
83912-26 – Interpretation and report
Turnaround Time
10 days
Specimen Requirements
- 10.0 mL (min. 9.0 mL) whole blood in EDTA
- 5.0 mL (min. 2.5 mL) bone marrow in EDTA
Specimen Stability
- Specimen must be received by MPLN within 36 hours of collection
- Stable at 2-8°C
Storage & Handling
Causes for Rejection
Specimen >48 hours old; Specimen clotted; Stored or shipped at incorrect temperature; Incorrect anticoagulant; Insufficient specimen volume
Reference Range
ABL Kinase domain mutation(s) detected and characterized / not detected
Related Content
BCR/ABL major and minor by quantitative PCR for MRD
Description
Screening of CML patients who (1) fail to achieve a complete hematologic response at 3 months (2) have no cytogenetic response at 6 months (3) fail to achieve a major cytogenetic response at 12 months, or (4) any loss of response (hematologic, cytogenetic or molecular).
References
- Jones D et al. (2009). Laboratory practice guidelines for detecting and reporting BCR/ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia. J Molec Diagn. 11:4-11.
- Lahaye et al. (2005). Response and resistance in 300 patients with BCR/ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer. 103:1659-1669.
Trademarks
Gleevec® is a registered trademark of the Novartis Pharmaceuticals Corporation.
